Marker Therapeutics
MRKR
28 hedge funds and large institutions have $8.82M invested in Marker Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 2 closing their positions.
53% more capital invested
Capital invested by funds: $5.78M → $8.82M (+$3.04M)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
0.84% more ownership
Funds ownership: 21.2% → 22.04% (+0.84%)
3% less funds holding
Funds holding: 29 → 28 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$310K |
| 2 |
AAM
AR Asset Management
West Hollywood,
California
|
+$168K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$113K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$87K |
| 5 |
Renaissance Technologies
New York
|
+$46.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAA
Matrix Asset Advisors
White Plains,
New York
|
-$140K |
| 2 |
VF
Virtu Financial
New York
|
-$63K |
| 3 |
HF
HRT Financial
New York
|
-$38K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7.9K |
MRKR Hedge Fund Activity: Q3 2023 in Review
28 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q3 2023, worth a combined $8.82M — up 53% from $5.78M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of MRKR and 1 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 9 added.
The largest buyer was Vanguard Group, adding an estimated $310K. The largest seller was Matrix Asset Advisors, cutting an estimated $140K.
- 28 institutional investors held Marker Therapeutics (MRKR) as of Q3 2023, down from 29 in Q2 2023.
- Funds reported $8.82M of Marker Therapeutics stock for Q3 2023, up 53% quarter-over-quarter.
- 1 fund opened new Marker Therapeutics positions in Q3 2023 and 2 closed out, a net change of -1 holder.
- The largest Marker Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $310K added.
- The largest Marker Therapeutics seller in Q3 2023 was Matrix Asset Advisors, an estimated $140K sold.
Based on aggregated 13F filings for Q3 2023.